Xiaoyu Zhu

University of Science and Technology of China (USTC) - Department of Hematology

96, Jinzhai Road

Hefei, Anhui 230026

China

SCHOLARLY PAPERS

2

DOWNLOADS

203

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

A First-in-Human Phase I/IIa Study of Allogeneic Double Negative T Cell for the Treatment of Relapsed AML Post Allo-HSCT

Number of pages: 30 Posted: 20 Apr 2021
University of Science and Technology of China (USTC) - Department of Hematology, University of Toronto - Toronto General Research Institute (UHN Research), University of Science and Technology of China (USTC) - Department of Hematology, University of Science and Technology of China (USTC, University of Science and Technology of China (USTC) - Department of Hematology, University of Science and Technology of China (USTC) - Department of Hematology, University of Science and Technology of China (USTC) - Department of Hematology, Hangzhou China and Ruichuang Biotechnology Co., Ltd. - WYZE Biotech Co., Ltd., Anhui Medical University - Lu'an Hospital, University of Science and Technology of China (USTC) - Department of Hematology, Hangzhou China and Ruichuang Biotechnology Co., Ltd. - WYZE Biotech Co., Ltd., University of Science and Technology of China (USTC) - Department of Hematology, Hangzhou China and Ruichuang Biotechnology Co., Ltd. - WYZE Biotech Co., Ltd., University of Science and Technology of China (USTC) - Department of Hematology, University of Science and Technology of China (USTC) - Department of Hematology, University of Science and Technology of China (USTC) - Department of Hematology, University of Toronto - Princess Margaret Cancer Centre, Hangzhou China and Ruichuang Biotechnology Co., Ltd. - WYZE Biotech Co., Ltd., University of Science and Technology of China (USTC) - Department of Hematology, University of Toronto - Toronto General Research Institute (UHN Research) and University of Science and Technology of China (USTC) - Department of Hematology
Downloads 158 (399,583)

Abstract:

Loading...

2.

Palbociclib Promotes the Antitumor Activity of Venetoclax Plus Azacitidine Against Acute Myeloid Leukemia

Number of pages: 23 Posted: 21 Apr 2022
University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, Department of Hematology, University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, Department of Hematology, University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, Department of Hematology, University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, Department of Hematology, University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, Department of Hematology, University of Science and Technology of China (USTC) - Department of Hematology, Zhengzhou University, University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, Department of Hematology and University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, Department of Hematology
Downloads 45 (876,463)

Abstract:

Loading...

AML, CDK6, Palbociclib, Venetoclax, Azacitidine, BCL-2, MCL-1, BCL-XL